Lupin launches Doxorubicin Hydrochloride Liposome Injection in US
ForDoz Pharma Corporation, USA (ForDoz) received an approval for its ANDA from the USFDA
ForDoz Pharma Corporation, USA (ForDoz) received an approval for its ANDA from the USFDA
Doxorubicin Hydrochloride Liposome Injection (RLD Doxil) had estimated annual sales of USD 42 million in the U.S. (IQVIA MAT May 2024)
Sales reflect continued strong growth in oncology and vaccines
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
The drug will target specific genetic mutations prevalent in certain types of cancers
It is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Subscribe To Our Newsletter & Stay Updated